Pages that link to "Item:Q1733138"
From MaRDI portal
The following pages link to A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate (Q1733138):
Displaying 12 items.
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145) (← links)
- A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents (Q3064270) (← links)
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents (Q3183236) (← links)
- Risk-Group-Specific Dose Finding Based on an Average Toxicity Score (Q3576932) (← links)
- (Q4428801) (← links)
- Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents (Q4967095) (← links)
- A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations (Q5135528) (← links)
- A combined proof of concept and dose finding study with multiple endpoints: A Bayesian adaptive design in chronic prostatitis/chronic pelvic pain syndrome (Q5208130) (← links)
- Flexible use of copula‐type model for dose‐finding in drug combination clinical trials (Q6055718) (← links)
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information (Q6085905) (← links)
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials (Q6626759) (← links)
